Previous Close | 0.8948 |
Open | 0.9023 |
Bid | 0.9414 x 1200 |
Ask | 0.9419 x 1200 |
Day's Range | 0.8613 - 0.9051 |
52 Week Range | 0.8500 - 2.2400 |
Volume | |
Avg. Volume | 13,321,798 |
Market Cap | 603.247M |
Beta (5Y Monthly) | 1.80 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2500 |
Earnings Date | May 01, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for OPK
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal antibodies and minimal anti-drug antibodies WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency v
Investors in OPKO Health, Inc. ( NASDAQ:OPK ) had a good week, as its shares rose 3.1% to close at US$1.00 following...
OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript February 27, 2024 OPKO Health, Inc. reports earnings inline with expectations. Reported EPS is $-0.09 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]